Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May 16:12:1569-1576.
doi: 10.2147/JPR.S190154. eCollection 2019.

Tapentadol: an overview of the safety profile

Enrico Polati  1 , Pier Luigi Canonico  2 , Vittorio Schweiger  1 , Massimo Collino  3
Affiliations
Review

Tapentadol: an overview of the safety profile

Enrico Polati et al. J Pain Res. .

Abstract

Long-term opioid therapy may be associated with analgesic efficacy and also predictable adverse events, including cardiovascular and pulmonary events, gastrointestinal disorders, endocrinological harms, psychological problems, impairment of driving ability, and risk of abuse. These effects of opioids are mostly due to the wide expression of the mu receptor. Tapentadol, a centrally acting analgesic, is the first agent of a new class of drugs (MOR-NRI), since it combines two mechanisms of action, namely µ-opioid receptor (MOR) agonism and noradrenaline reuptake inhibition. Noteworthy, MOR activation with tapentadol is markedly lower compared with that exerted by classical opioids, thus likely resulting in fewer opioid-related adverse effects. In this review, we discuss current safety data on tapentadol, with a focus on some specific events, risk of abuse, and driving ability, a well-accepted proxy of the ability of taking critical decisions.

Keywords: pain; safety; tapentadol.

PubMed Disclaimer

Conflict of interest statement

Pier Luigi Canonico reports grants and personal fees from Roche, Otsuka, Teva, Angelini. He also reports personal fees from MSD, Eli Lilly, Biogen, Novartis, Celgene, Amicus, Jazz Pharmaceuticals, Tesaro, Lundbeck, Merck Serono, Pierre Fabre, Takeda, Astra Zeneca, Shire, Abbvie, Menarini, Astellas, Novo Nordisk, Sanofi, Boehringer Ingelheim, Bial, Amgen, Bayer, UCB, Leo Pharma, and Intercept, outside the submitted work. All authors report no other conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Els C, Jackson TD, Kunyk D, et al. Adverse events associated with medium- and long-term use of opioids for chronic non-cancer pain: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;10:CD012509. - PMC - PubMed
    1. Nafziger AN, Barkin RL. Opioid therapy in acute and chronic pain. J Clin Pharmacol. 2018;58(9):1111–1122. doi:10.1002/jcph.1276 - DOI - PubMed
    1. Hegmann KT, Weiss MS, Bowden K, et al. ACOEM practice guidelines: opioids and safety-sensitive work. J Occup Environ Med. 2014;56(7):e46–53. doi:10.1097/JOM.0000000000000237 - DOI - PubMed
    1. Murphy DL, Lebin JA, Severtson SG, Olsen HA, Dasgupta N, Dart RC. Comparative rates of mortality and serious adverse effects among commonly prescribed opioid analgesics. Drug Saf. 2018;41:787–795. doi:10.1007/s40264-018-0660-4 - DOI - PubMed
    1. Kress HG. Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain. 2010;14:781–783. doi:10.1016/j.ejpain.2010.06.017 - DOI - PubMed